WILMINGTON, N.C.--(BUSINESS WIRE)--The PPD clinical research business of Thermo Fisher Scientific, the world leader in serving science, has been honored for industry leadership in digital services by Information Services Group (ISG), a leading global technology research and advisory firm. The business was recognized as an ISG Provider Lens Leader for its digital transformation services in clinical development and patient engagement, as well as pharmacovigilance and regulatory affairs.
ISG’s honor focuses on the business’ ability to provide access to patients to clinical trials of promising new medical therapies in a more efficient and effective way. It also recognizes the ability to help pharmaceutical and biotech customers accelerate the delivery of safe and effective medicines to the marketplace while addressing issues of patient diversity, health equity and sustainability in clinical research.
In the 2024 ISG Provider Lens™ Life Sciences Digital Services Global Report, ISG specifically recognized Thermo Fisher’s clinical research business for its decentralized trials capabilities, full-spectrum expertise across various therapeutic areas and customized, diverse patient engagement solutions. ISG highlighted the strength of the business’ robust patient recruitment and retention strategies that continue to overcome common barriers in clinical trials, such as lack of awareness, access, trust, inconvenience and socioeconomic challenges.
Additionally, the report highlighted the business’ advanced disease simulation and modeling, along with its comprehensive pharmacovigilance and regulatory solutions, which includes artificial intelligence integration and machine learning. The PPD clinical research business leverages a diverse range of technology solutions to propel advancements in areas such as case processing, safety profiling, regulatory intelligence collection and compilation.
“We are honored to once again receive this recognition from ISG, affirming our steadfast market presence and exceptional industry leadership,” said Brittany Erana, vice president and general manager, Patient First Digital Solutions, clinical research, Thermo Fisher Scientific. “We are dedicated to revolutionizing patient-centered clinical research by harnessing cutting-edge patient and site-enabling technology, while adopting a comprehensive approach that prioritizes enhancing the patience experience. This unwavering commitment to patients empowers us and our customers to introduce life-changing medicines to the global market.”
In 2023, Thermo Fisher invested $1.3 billion in research and development to deliver new technologies across all businesses, including the PPD clinical research business. For its ISG Provider Lens report, ISG conducted an independent review of life science companies offering digital services, then selected the top 20 companies for a deep analysis and placement on its Provider Lens Quadrant. ISG’s findings cover defined technology and service categories, as well as industry-specific capabilities.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
